199 related articles for article (PubMed ID: 10697267)
1. Androgen receptors: a marker to increase sensitivity for identifying breast cancer in skin metastasis of unknown primary site.
Bayer-Garner IB; Smoller B
Mod Pathol; 2000 Feb; 13(2):119-22. PubMed ID: 10697267
[TBL] [Abstract][Full Text] [Related]
2. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms.
Wallace ML; Longacre TA; Smoller BR
Mod Pathol; 1995 Dec; 8(9):897-901. PubMed ID: 8751328
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas.
Busam KJ; Tan LK; Granter SR; Kohler S; Junkins-Hopkins J; Berwick M; Rosen PP
Mod Pathol; 1999 Aug; 12(8):786-93. PubMed ID: 10463481
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and progesterone receptors in primary eccrine carcinoma.
Voytek TM; Ricci A; Cartun RW
Mod Pathol; 1991 Sep; 4(5):582-5. PubMed ID: 1661896
[TBL] [Abstract][Full Text] [Related]
5. Improved measurement of androgen receptors in human breast cancer.
Lea OA; Kvinnsland S; Thorsen T
Cancer Res; 1989 Dec; 49(24 Pt 1):7162-7. PubMed ID: 2582456
[TBL] [Abstract][Full Text] [Related]
6. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors.
Isola JJ
J Pathol; 1993 May; 170(1):31-5. PubMed ID: 8100853
[TBL] [Abstract][Full Text] [Related]
10. Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast.
Cho LC; Hsu YH
Kaohsiung J Med Sci; 2008 May; 24(5):227-32. PubMed ID: 18508419
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases.
Briffod M; Hacène K; Le Doussal V
Mod Pathol; 2000 Aug; 13(8):841-50. PubMed ID: 10955449
[TBL] [Abstract][Full Text] [Related]
12. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
13. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue].
Schulze MH; Buchmann J
Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188
[TBL] [Abstract][Full Text] [Related]
14. [Immunohistochemical investigation of estrogen and progesterone receptors in breast tumors].
Ellinidi VN; Anikseeva NV; Goncharova OA; Krasnozhon DA; Fedorov KA
Vopr Onkol; 2004; 50(2):234-6. PubMed ID: 15176229
[TBL] [Abstract][Full Text] [Related]
15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
16. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
17. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
Lertsanguansinchai P; Chottetanaprasith T; Chatamra K; Sampatanukul P; Wannakrairot P; Rojpornpradit P; Shotelersuk K; Lertbutsayanukul C; Boonjunwetwat D; Vajragupta L
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S193-202. PubMed ID: 12188412
[TBL] [Abstract][Full Text] [Related]
18. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
19. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
20. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
